Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Roche and Agilent to Provide Continued Service and Support to Roche NimbleGen Microarray Customers

Published: Wednesday, November 07, 2012
Last Updated: Wednesday, November 07, 2012
Bookmark and Share
Transition of services beginning immediately.

Roche and Agilent Technologies, Inc. announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases-out its NimbleGen array production and services. Researchers using NimbleGen microarrays for all applications, including comparative genomic hybridization, chromatin immunoprecipitation-on-chip, DNA methylation, and gene expression can transition to Agilent arrays, effective immediately, with minimal disruption. The similarities of the technologies and products from both companies provide an optimal transition path and the ability to run Agilent microarrays on the NimbleGen MS 200 Microarray Scanner.

“This global collaboration provides our customers with a confident and straightforward solution to move from NimbleGen to Agilent microarrays,” said Dan Zabrowski, Head of Roche Applied Science. “With Agilent as a leading global supplier of microarray technology, we are convinced researchers will be provided with the highest compatibility to NimbleGen products and services, and believe that they will continue to receive the exceptional service and support they have come to expect.”

“We are working closely with Roche to help customers make the transition to Agilent microarray products,” said Robert Schueren, vice president and general manager of Agilent’s Genomics Systems Division. “Our field service personnel are working directly with individual researchers to help convert their NimbleGen designs, and they will continue to provide enhanced service and support throughout the transition period and beyond. Additionally, Agilent is also enabling customers to read their arrays on NimbleGen scanners, eliminating the need to invest in capital equipment.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche Introduces Enhanced Whole Exome Sequencing Solution
The company has announced the launch of the SeqCap EZ MedExome Target Enrichment Kit1.
Wednesday, September 23, 2015
Roche Invests For The Future In Its Basel Site
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development.
Thursday, October 23, 2014
Roche, Garvan Institute Epigenomic Partnership
Roche and the Garvan Institute of Medical Research today announce a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.
Wednesday, August 20, 2014
Roche, Oryzon Announce Epigenetics Collaboration
Collaboration spans research, development and commercialization of LSD1 inhibitors for oncology, haematology and non-malignant conditions.
Monday, April 07, 2014
Roche 454 Sequencing Systems Successfully Resolve Genetic Mutations in Blood Cancer Cases
International study presented at ASH Meeting demonstrates the potential of 454 Sequencing Systems to comprehensively characterize an individual’s blood cancer type to guide personalized therapy decisions.
Thursday, December 13, 2012
Roche's Troponin T Nominated for International Inventor Award
European Patent Office nominates the team of Klaus Hallermayer from Roche Penzberg, jointly with Prof. Hugo Katus from the University of Heidelberg.
Monday, June 11, 2012
Roche and Life Technologies Corporation Sign New PCR IVD Licenses
Companies announced that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.
Thursday, February 23, 2012
Roche and Labcyte Integrate Echo and LightCycler Systems to Increase Performance of qPCR-based RNA/DNA Analyses
Companies cooperate around high-speed, miniaturized quantitative PCR (qPCR) to monitor the expression of tens to thousands of genes for therapeutic research.
Wednesday, December 07, 2011
Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
Roche NimbleGen, Inc. and BGI, a large genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology for Human Disease and Biomedical Research.
Tuesday, November 29, 2011
Complete Genome of Cynomolgus Monkey and Novel Gene Expression Microarray for Drug Safety Assessment
A team of researchers from Roche have generated the first draft genome sequence of the cynomolgus monkey and developed a novel microarray design for in depth expression profiling for use in preclinical drug safety research.
Thursday, September 22, 2011
Roche Buys Full Rights to Danoprevir from InterMune
Agreement reinforces Roche’s leadership in the fight against hepatitis C.
Wednesday, October 13, 2010
Roche and reMYND Enter Agreement to Develop First-in-Class Disease-Modifying Treatments for Parkinson’s and Alzheimer’s Disease
Novel therapies to target unmet needs in neurodegenerative disorders.
Tuesday, September 07, 2010
Macrogen, Inc. Certified as NimbleGen Array Service Provider for Korea
Macrogen has been certified to process customer samples for NimbleGen CGH/CNV services in their lab in Seoul.
Wednesday, July 14, 2010
Roche and Start Initiative for Early Discovery of New Diseases
The joint project is aimed to demonstrate the feasibility of developing a multidisciplinary surveillance, research and response system.
Wednesday, July 29, 2009
Roche Applied Science Opens Application Support Center in Shanghai
The new Application Support Center will apply broad range of technologies to a diverse range of life science research topics.
Friday, May 29, 2009
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Coronavirus Breakthrough
Protein mutation affects spread and virulence of respiratory virus.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos